Immunotherapy drug aims to stop deadly skin cancer's return in high-risk patients
NCT ID NCT03271372
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether the immunotherapy drug avelumab can keep Merkel cell carcinoma from returning in patients whose cancer has spread to lymph nodes and who have already had surgery or radiation. About 100 adults will receive either avelumab or a placebo every two weeks for up to a year. The goal is to see if avelumab helps the immune system attack any remaining cancer cells and improves survival without the cancer coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III MERKEL CELL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of California Irvine Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
University of Colorado Cancer Center University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States